Tenecteplase real-world data: A three phase sequential comparison.

ABSTRACT:

Introduction

The New Zealand (NZ) Central Region Stroke Network, serving 1.17 million catchment population, changed to tenecteplase for stroke thrombolysis in 2020 but was forced to revert to Alteplase in 2021 due to a sudden cessation of drug supply. We used this unique opportunity to assess for potential before and after temporal trend confounding.

Patients and methods

In NZ all reperfused patients are entered prospectively into a national database for safety monitoring. We assessed Central Region patient outcomes and treatment metrics over three time periods: alteplase use (January 2018-January 2020); during switch to tenecteplase (February 2020-February 2021) and after reverting to alteplase (February 2021-December 2022) adjusting regression analyses for hospital, age, o

SUBMITTER: Ranta A 

PROVIDER: S-EPMC10683726 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature